Treg cell therapy for type 1 diabetes
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests whether giving your own regulatory T cells (a type of immune cell) back to you can help slow or stop the immune attack on your pancreas in type 1 diabetes. It is for people aged 8 to 65 who still make some insulin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with type 1 diabetes
- You are between 8 and 65 years old
- You have at least one diabetes-related antibody in your blood, or your fasting C-peptide level is 300 pmol/L or below
- You are willing to sign a consent form and follow the study rules
- You must not have uncontrolled diabetic ketoacidosis, known cancer, severe allergies, or certain other serious health problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a combination approach to help your immune system stop attacking insulin-producing cells in newly diagnosed type 1 diabetes. It aims to preserve your body's ability to make insulin and slow disease progression.
This trial is testing a one-time cell treatment (CARC-101C) for people recently diagnosed with type 1 diabetes. The goal is to see if it is safe and can help preserve the body's ability to make some insulin.
This trial tests a new treatment made from stem cells that may help people with diabetes who have dangerous low blood sugar episodes. It aims to see if these cells can replace some of the pancreas function and prevent severe hypoglycemia.
This trial tests a new treatment using your own immune cells (called Tregs) that are modified to target and calm the immune attack on the pancreas. It is for people diagnosed with stage 3 type 1 diabetes within the last 12 to 24 months who still make some insulin.
This trial tests a new combination treatment for children who have been diagnosed with stage 1 type 1 diabetes, meaning they have some markers but do not yet need insulin. The treatment uses special immune cells (Treg cells) and an antibody (anti-CD20) to try to preserve the body's ability to make insulin.
This trial tests a new gene therapy that uses your own blood stem cells to treat type 1 diabetes soon after diagnosis. It aims to see if this treatment can help preserve your body's ability to make insulin.
Hear when a new Type 1 Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.